Immunity against respiratory pathogens is often short-term, and, consequently, there is an
unmet need for the effective prevention of such infections. One such infectious disease is …

Rapid molecular testing for severe acute respiratory coronavirus 2 (SARS-CoV-2) variants
may contribute to the development of public health measures, particularly in resource-limited …

There is an urgent need to develop effective antiviral drugs to prevent the viral infection
caused by constantly circulating SARS-CoV-2 as well as its variants. The main protease …

Several reports documented a specific effect of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) on blood pressure (BP), during and after the acute phase of …

In the last year of pandemic, several variants of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) have been identified and monitored. Indeed, the persisting …

Until February 2023, the majority of COVID-19 cases were associated with SARS-CoV-2
subvariants, such as BF. 7,[1] BQ. 1,[1] BQ. 1.1,[1] and XBB. 1.5,[1] and XBB. 1.9.[2] …

Central to the pathogenicity of SARS-CoV-2 is the spike (S) protein, which relies on furin
protease and TMPRSS2 to recognize and cleave the sequence to complete the invasion of …

Despite the waning threat of the COVID-19 pandemic, its detrimental impact on global health
persists. Regardless of natural immunity or immunity obtained through vaccination …

Background Most of current approved vaccines, based on a Spike-only as single
immunogen, fall short of producing a full-blown T-cell immunity. SARS-CoV-2 continues to …

Immunity against respiratory pathogens is often short-term, and consequently there is an
unmet need for effective prevention of such infections. One such infectious disease is COVID …